Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Cash & Equivalents (2017 - 2026)

Cogent Biosciences' Cash & Equivalents history spans 10 years, with the latest figure at $241.2 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 91.43% to $241.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $241.2 million through Mar 2026, up 91.43% year-over-year, with the annual reading at $312.0 million for FY2025, 217.84% up from the prior year.
  • Cash & Equivalents came in at $241.2 million for Q1 2026, down from $312.0 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $325.6 million in Q2 2022 to a low of $53.2 million in Q4 2023.
  • The 5-year median for Cash & Equivalents is $139.9 million (2022), against an average of $161.4 million.
  • Year-over-year, Cash & Equivalents tumbled 61.95% in 2023 and then surged 217.84% in 2025.
  • Cogent Biosciences' Cash & Equivalents stood at $139.9 million in 2022, then crashed by 61.95% to $53.2 million in 2023, then soared by 84.42% to $98.2 million in 2024, then soared by 217.84% to $312.0 million in 2025, then dropped by 22.69% to $241.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Cash & Equivalents are $241.2 million (Q1 2026), $312.0 million (Q4 2025), and $125.3 million (Q3 2025).